Veeda to adopt cancer hospitals for easy access to patient pool

A clinical research firm Veeda Clinical Research Pvt. Ltd, India’s third-largest clinical trials company by revenue is proposing a project, wherein it is adopting at least a dozen cancer hospitals in tier-II and tier-III cities across the country to ensure easy access to a wider patient pool for its drug test projects in India. The move is part of its plan to float a dedicated oncology (cancer) drug trials division within the group. Adopting these hospitals with financial as well as technical support from multinational drug makers, Veeda claims it helps also upgrading the facilities with modern equipment and improve health-care standards in these cancer hospitals. This is the first time a clinical research company in the world is proposing a project of this kind, which will not only ensure availability of variety of cancer patients for their trials but will also offer new drugs and better facilities to these under-served hospitals in the rural region. Global drug giants such as GSK Plc., AstraZeneca Plc., Pfizer Inc. and Sanofi Aventis, all focused on cancer drug research are helping Veeda’s hospital project. A ready access to a patient pool from different regions and races is an important advantage for a clinical trial services company.However there are some reservations regarding this too. Improving facilities in rural cancer hospitals in a country like India is a most pertinent move, but could possibly lead to exploitation of the uninformed cancer patients in these hospitals in helping to test new drugs of the profit-making pharmaceutical companies. Veeda is also mulling two overseas acquisitions, Currently in talks with two medium-level CROs in central Europe and Canada which specialize in cancer drug research. Veeda, has operations in the UK, Germany, Belgium, Brussels and the US. It handles drug trials for some nine of the top 15 global drug companies. In India, Veeda trails Lotus Labs Ltd and Lambda Therapeutic Research Ltd in terms of revenue in the sector.


Follow and connect with us on Facebook, Twitter, LinkedIn, Elets video

Eletsonline News

Follow us on

Most Popular

200000+ Subscribers read it every day.
Subscribe Newsletter
To Top